These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12372923)

  • 1. Treatment with vitamin K antagonists: frequency of indications and appropriateness of continuation.
    van Der Heijden JF; Remkes MG; Büller HR; Vermeulen M
    Pathophysiol Haemost Thromb; 2002; 32(3):111-4. PubMed ID: 12372923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.
    Siragusa S; Malato A; Saccullo G; Iorio A; Di Ianni M; Caracciolo C; Coco LL; Raso S; Santoro M; Guarneri FP; Tuttolomondo A; Pinto A; Pepe I; Casuccio A; Abbadessa V; Licata G; Battista Rini G; Mariani G; Di Fede G
    Am J Hematol; 2011 Nov; 86(11):914-7. PubMed ID: 21953853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists.
    Kooistra HA; Calf AH; Piersma-Wichers M; Kluin-Nelemans HC; Izaks GJ; Veeger NJ; Meijer K
    JAMA Intern Med; 2016 Aug; 176(8):1176-83. PubMed ID: 27379731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
    Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged heparin and vitamin K antagonist regimen for early non-obstructive thrombosis of mechanical mitral valve prostheses.
    Laurent M; Lelong B; Verhoye JP; Khattar C; de Place C; Matali P; Chabanne C; Leurent G; Langanay T; Leguerrier A
    J Heart Valve Dis; 2008 Sep; 17(5):533-41. PubMed ID: 18980087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients.
    Torn M; Cannegieter SC; Bollen WL; van der Meer FJ; van der Wall EE; Rosendaal FR
    Arch Intern Med; 2009 Jul; 169(13):1203-9. PubMed ID: 19597069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors of vitamin K antagonist overcoagulation.
    Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
    QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation].
    Sibai MS; Bellarbre F; Ghazali N; Bureau ML; Priner M; Ingrand P; Paccalin M
    Geriatr Psychol Neuropsychiatr Vieil; 2014 Mar; 12(1):20-4. PubMed ID: 24647235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fourteen-year follow-up from CABADAS: vitamin K antagonists or dipyridamole not superior to aspirin.
    Veeger NJ; Zijlstra F; Hillege HL; van der Meer J;
    Ann Thorac Surg; 2010 Nov; 90(5):1515-21. PubMed ID: 20971252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous massive pectoral hematoma induced by vitamin K antagonist therapy: a case report.
    Benbouchta K; Mrabet A; Kallel O; El Ouafi N; Bazid Z
    Pan Afr Med J; 2021; 38():324. PubMed ID: 34285747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.
    Brekelmans MP; Kappelhof M; Nieuwkerk PT; Nierman M; Buller HR; Coppens M
    Neth J Med; 2017 Mar; 75(2):50-55. PubMed ID: 28276323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.